PT - JOURNAL ARTICLE AU - Mosley, Philip E. AU - Windels, François AU - Morris, John AU - Coyne, Terry AU - Marsh, Rodney AU - Giorni, Andrea AU - Mohan, Adith AU - Sachdev, Perminder AU - O’Leary, Emily AU - Boschen, Mark AU - Sah, Pankaj AU - Silburn, Peter A. TI - A Randomised, Double-Blind, Sham-Controlled Trial of Deep Brain Stimulation of the Bed Nucleus of the Stria Terminalis for Treatment-Resistant Obsessive-Compulsive Disorder AID - 10.1101/2020.10.24.20218024 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.24.20218024 4099 - http://medrxiv.org/content/early/2020/10/27/2020.10.24.20218024.short 4100 - http://medrxiv.org/content/early/2020/10/27/2020.10.24.20218024.full AB - Deep brain stimulation (DBS) is a promising treatment for severe, treatment-resistant obsessive-compulsive disorder (OCD). Here, nine participants (four females, mean age 47.9 ±10.7 years) were implanted with DBS electrodes bilaterally in the bed nucleus of the stria terminalis (BNST). Following a one-month postoperative recovery phase, participants entered a three-month randomised, double-blind, sham-controlled phase before a twelve-month period of open-label stimulation incorporating a course of cognitive behavioural therapy (CBT). The primary outcome measure was OCD symptoms as rated with the Yale-Brown Obsessive-Compulsive Scale (YBOCS). In the blinded phase, there was a significant benefit of active stimulation over sham (p = 0.025, mean difference 4.9 points). After the open phase, the mean reduction in YBOCS was 16.6 ±1.9 points (Χ2 (11) = 39.8, p = 3.8 × 10−5), with seven participants classified as responders. CBT resulted in an additive YBOCS reduction of 4.8 ±3.9 points (p = 0.011). There were two serious adverse events related to the DBS device, the most severe of which was an infection during the open phase necessitating device explantation. There were no psychiatric adverse events related to stimulation. An analysis of the structural connectivity of each participant’s individualised stimulation field isolated right-hemispheric fibres associated with YBOCS reduction. These included subcortical tracts incorporating the amygdala, hippocampus and stria terminalis, in addition to cortical regions in the ventrolateral and ventromedial prefrontal cortex, parahippocampal, parietal and extrastriate visual cortex. In conclusion, this study provides further evidence supporting the efficacy and tolerability of DBS for individuals with otherwise treatment-refractory OCD and identifies a connectivity fingerprint associated with clinical benefit.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialU1111-1146-0992Funding StatementThe trial was funded by the University of Queensland through the Queensland Brain Institute in partnership with Medtronic. Medtronic provided the PC+S devices, 3389 stimulating electrodes, physician programmers and related equipment. Medtronic also made a cash contribution to the research costs. Medtronic had no role in the design of the experimental protocol, data collection, analysis or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Queensland HREC UnitingCare HRECAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA de-identified data set containing demographic and outcome data can be provided by Dr Philip Mosley (Philip.Mosley{at}qimrberghofer.edu.au) on application, subject to institutional review board approval. Local ethics caveats and clinical privacy issues prohibit sharing of individual imaging data but a copy of the Lead-DBS group analysis database can be supplied.